Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know

    Research output: Contribution to journalReviewResearchpeer-review

  4. Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo

    Research output: Contribution to journalReviewResearchpeer-review

  1. MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Ovarian cancer is the most lethal gynaecological malignancy. The cancer initially presents with non‑specific symptoms; thus, it is typically not discovered until the patient has reached the late, considerably more lethal, stages of the disease. Research focus is currently on finding novel biomarkers, especially for early detection and stratification of the disease. One promising approach has been to focus on mutations or variations in the genetic code that are associated with the risk of developing ovarian cancer. A certain heritable component is already known regarding genes such as BRCA1/2, TP53, MSH6, BRIP1 and RAD51C, yet these are estimated to only account for ~3.1% of the total risk. Recent advances in sequencing technologies have enabled the investigation of hundreds of thousands of genetic variants in genome‑wide association studies in tens of thousands of patients, which has led to the discovery of 108 (39 loci with P<5.0x10‑8) novel susceptibility loci for ovarian cancer, presented in this review. Using the published variants in a patient cohort screening, together with variants identified in our ongoing whole exome sequencing project, future aims are to ascertain whether certain of the novel variants could be used as biomarkers for early diagnosis and/or treatment decisions.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume44
Issue number5
Pages (from-to)1599-1608
Number of pages10
ISSN1661-6596
DOIs
Publication statusPublished - Nov 2019

ID: 59089279